Akebia Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AX9 vs TKNO, ORGO, SIGA: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (STU:AX9) has a Buyback Yield % of -0.57 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Akebia Therapeutics and its competitors. According to the industry distribution chart, Akebia Therapeutics ranks #150 out of 292 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is Akebia Therapeutics' Buyback Yield % too high?
Akebia Therapeutics' current Buyback Yield % is -0.57. Based on the distribution chart, Akebia Therapeutics ranks #150 out of 292 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Buyback Yield % compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #150 out of 292 companies for Buyback Yield %. This places Akebia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Buyback Yield % is -0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.11, compared to a current price of €1.08 — trading 2.8% below its estimated fair value. The current Buyback Yield % is -0.57. Akebia Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Buyback Yield % is -0.57 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €1.08 is trading 2.8% below its estimated GF Value™ of €1.11.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for STU:AX9:
Buyback Yield %: -0.57
GF Value™: €1.11 vs. price of €1.08 (2.8% below fair value)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
47GF Score
Get the complete analysis for STU:AX9
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
